These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33733758)

  • 1. Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.
    Zhang H; Peng X; Dai Y; Shao J; Ji Y; Sun Y; Liu B; Cheng X; Ai J; Duan W
    J Med Chem; 2021 Apr; 64(7):3956-3975. PubMed ID: 33733758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.
    Tan L; Zhang Z; Gao D; Luo J; Tu ZC; Li Z; Peng L; Ren X; Ding K
    J Med Chem; 2016 Jul; 59(14):6807-25. PubMed ID: 27379978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy.
    Lan Y; Peng X; Ji Y; Su Y; Duan W; Ai J; Zhang H
    Eur J Med Chem; 2024 Feb; 265():116045. PubMed ID: 38128234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
    Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
    Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 10
    Zhan Z; Ji Y; Su H; Fang C; Peng X; Liu Q; Dai Y; Lin D; Xu Y; Ai J; Duan W
    J Med Chem; 2023 Jan; 66(1):220-234. PubMed ID: 36524812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
    Xu D; Sun D; Wang W; Peng X; Zhan Z; Ji Y; Shen Y; Geng M; Ai J; Duan W
    Eur J Med Chem; 2021 Aug; 220():113497. PubMed ID: 33957388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
    Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
    Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor.
    Yu Y; Jang M; Miyashiro J; Clark RF; Zhu GD; Gong J; Dai Y; Frey RR; Penning TD; Kim H; Lee HK; Kim JK; Ryu KM; Park SJ; Yoon T; Li T; Kurnick MD; Kapecki NJ; Li L; Gorman JV; Montgomery DA; Manaves V; Bromberg KD; Doktor SZ; Thakur A; Wang J; Smith HA; Buchanan FG; Ferguson DC; Torrent M; Jakob CG; Qiu W; Upadhyay AK; Martin RL; Lai A; Michaelides MR
    J Med Chem; 2024 Oct; 67(19):17000-17032. PubMed ID: 39283694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
    Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.
    Chan S; Zhang Y; Wang J; Yu Q; Peng X; Zou J; Zhou L; Tan L; Duan Y; Zhou Y; Hur H; Ai J; Wang Z; Ren X; Zhang Z; Ding K
    J Med Chem; 2022 Nov; 65(22):15374-15390. PubMed ID: 36358010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.
    Goff D; Zhang J; Heckrodt T; Yu J; Ding P; Singh R; Holland S; Li W; Irving M
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3766-3771. PubMed ID: 28711351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AXL regulates mesothelioma proliferation and invasiveness.
    Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
    Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
    Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
    Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
    Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AXL kinase as a novel target for cancer therapy.
    Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
    Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
    Zhu C; Wei Y; Wei X
    Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
    Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
    Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
    J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
    Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
    Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.